Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis in a cross-over design

Key facts

Study ID

NCT03757351

Run by

Sanofi

People needed

15

Starts

2018-12-14

Expected to finish

2020-06-18

Last updated by the study team

2025-09-22

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Bioclinica — Orlando, Florida, United States
• PRA Health Sciences — Salt Lake City, Utah, United States
• CHDR — Leiden, South Holland, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.